Heterogeneity in PD-L1 expression in malignant peritoneal mesothelioma with systemic or intraperitoneal chemotherapy

Programmed death-ligand 1 (PD-L1) expression has been described in patients with malignant peritoneal mesothelioma (MPM), but treatment strategies utilising immune checkpoint inhibition are yet to be defined. Here, we examine levels of PD-L1 expression in MPM patients treated with systemic and/or in...

Descripción completa

Detalles Bibliográficos
Autores principales: White, Michael G., Schulte, Jefree J., Xue, Lai, Berger, Yaniv, Schuitevoerder, Darryl, Vining, Charles C., Kindler, Hedy L., Husain, Aliya, Turaga, Kiran K., Eng, Oliver S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7851380/
https://www.ncbi.nlm.nih.gov/pubmed/33100328
http://dx.doi.org/10.1038/s41416-020-01130-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7851380/
https://www.ncbi.nlm.nih.gov/pubmed/33100328
http://dx.doi.org/10.1038/s41416-020-01130-x

Ejemplares similares